nach oben

Erschienen in:

12.05.2017 | Magnetic Resonance

Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI

verfasst von: Jiyoung Hwang, Young Kon Kim, Ji Hye Min, Seo-Youn Choi, Woo Kyung Jeong, Seong Sook Hong, Hyun-joo Kim, Soohyun Ahn, Hyeon Seon Ahn

Erschienen in: European Radiology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the added value of capsule, septum, and T2 hyperintense foci for differentiating large hepatocellular carcinoma (HCC; ≥ 5 cm) from intrahepatic cholangiocarcinoma (ICC) using gadoxetic acid MRI.

Methods

The study included 116 patients (94 men, 22 women; mean age, 56.8 years) with surgically confirmed HCCs (n = 87, 5.0–18.0 cm) or ICCs (n = 29, 5.0–14.0 cm) who underwent gadoxetic acid MRI. Three observers independently reviewed MRIs in two sessions, examining enhancement patterns only and then adding capsule, septum, and T2 hyperintense foci. Reviewers used a five-point scale to score accuracy, sensitivity, and specificity.

Results

A significant increase was observed in accuracy when ancillary features (96.1–98.3%) were added compared to enhancement pattern only (83.6–88.4%; p ≤ 0.02). Sensitivity was significantly increased with combined reading (97.1–98.3%) compared to enhancement features only (81.6–88.5%; p ≤ 0.006) for two observers, with no difference in specificity (84.5–89.7% vs. 86.2–98.3%; p > 0.05). We found substantial to excellent interobserver agreement for ancillary features (0.598–0.976).

Conclusion

Adding capsule, septum, and T2 hyperintense foci to enhancement patterns for gadoxetic acid MRI increased diagnostic performance for characterizing large HCC by differentiating it from ICC.

Key Points

• Capsule, septum, and T2 hyperintense foci were useful for characterizing large HCC.

• Adding ancillary features to enhancement pattern increased accuracy for diagnosing large HCC.

• Interobserver agreement was substantial to excellent for ancillary features.

Nur mit Berechtigung zugänglich

Bruix J, Reig M, Rimola J et al (2011) Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 54:2238–2244CrossRef

Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654CrossRef

Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L (2012) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer 1:190–200CrossRef

Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRef

Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674–682CrossRef

Fujita N, Nishie A, Kubo Y et al (2015) Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol 25:211–220CrossRef

Chong YS, Kim YK, Lee MW et al (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67:766–773CrossRef

Blaschke EM, Rao VL, Xiong L et al (2016) Multiphase multi-detector row computed tomography imaging characteristics of large (>5 cm) focal hepatocellular carcinoma. J Comput Assist Tomogr 40:493–497CrossRef

Kanata N, Yoshikawa T, Ohno Y et al (2013) HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT. Magn Reson Imaging 31:17–22CrossRef

10.

Kim SJ, Lee JM, Han JK, Kim KH, Lee JY, Choi BI (2007) Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189:1428–1434CrossRef

11.

Xu J, Igarashi S, Sasaki M et al (2012) Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 32:1156–1164CrossRef

12.

Kim R, Lee JM, Shin CI et al (2016) Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol 26:1808–1817CrossRef

13.

Asayama Y, Nishie A, Ishigami K et al (2015) Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol 21:96–104CrossRef

14.

Park HJ, Jang KM, Kang TW et al (2016) Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 26:3102–3111CrossRef

15.

Lee KH, O'Malley ME, Haider MA, Hanbidge A (2004) Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol 182:643–649CrossRef

16.

van den Bos IC, Hussain SM, Dwarkasing RS et al (2007) MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 26:1548–1555CrossRef

17.

Marti-Bonmati L, Talens A, del Olmo J et al (1993) Chronic hepatitis and cirrhosis: evaluation by means of MR imaging with histologic correlation. Radiology 188:37–43CrossRef

18.

Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef

19.

Choi SH, Byun JH, Lim YS et al (2016) Diagnostic criteria for hepatocellular carcinoma 3cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 64:1099–1107CrossRef

20.

Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRef

21.

Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK (2016) Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. doi:10.1002/jmri.25287 CrossRefPubMed

22.

Ishigami K, Yoshimitsu K, Nishihara Y et al (2009) Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 250:435–443CrossRef

23.

American College of Radiology (2014) Liver Imaging Reporting and Data System Available via http://www.acr.org/Quality-Safety/Resources/LIRADS. Accessed July, 18 2016

24.

Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197:W44–W52CrossRef

25.

Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183:819–825CrossRef

26.

Bennett BM (1972) On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics 28:793–800CrossRef

27.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef

28.

Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB (2008) Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 28:747–769CrossRef

29.

Nakamura Y, Toyota N, Date S et al (2011) Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results. J Comput Assist Tomogr 35:723–727CrossRef

30.

Lim JH, Choi D, Park CK, Lee WJ, Lim HK (2006) Encapsulated hepatocellular carcinoma: CT-pathologic correlations. Eur Radiol 16:2326–2333CrossRef

31.

Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA (2010) Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 32:360–366CrossRef

32.

An C, Rhee H, Han K et al (2016) Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol. doi:10.1007/s00330-016-4634-6 CrossRefPubMed

33.

Khatri G, Merrick L, Miller FH (2010) MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 18:421–450, x CrossRef

34.

Zech CJ, Reiser MF, Herrmann KA (2009) Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 27:114–124CrossRef

35.

Fujimoto M, Nakashima O, Komuta M, Miyaaki T, Kojiro M, Yano H (2010) Clinicopathological study of hepatocellular carcinoma with peliotic change. Oncol Lett 1:17–21CrossRef

Titel: Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI
verfasst von: Jiyoung Hwang
Young Kon Kim
Ji Hye Min
Seo-Youn Choi
Woo Kyung Jeong
Seong Sook Hong
Hyun-joo Kim
Soohyun Ahn
Hyeon Seon Ahn
Publikationsdatum: 12.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 11/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-017-4846-4

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI